Lynx1 Capital Management’s Neurogene NGNE Stock Holding History

Lynx1 Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-154,728	Closed	-$2.57M	–	23
2023 Q2	$2.57M	Buy	154,728 +33,312	+27%	+$546K	1.68%	10
2023 Q1	$1.7M	Buy	121,416 +6,859	+6%	+$80.4K	1.42%	11
2022 Q4	$1.17M	Buy	+114,557	New	+$1.18M	1.01%	11

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lynx1 Capital Management's NGNE Position: Q3 2023 in Review

Lynx1 Capital Management sold out of Neurogene (NGNE) in Q3 2023, closing a stake of 154,728 shares — an estimated $2.57M sold.

Lynx1 Capital Management first reported a position in NGNE in Q4 2022 and held it in 3 quarters. The position peaked at $2.57M in Q2 2023. 31 funds tracked by Wall St. Rank hold NGNE as of Q3 2023.

Lynx1 Capital Management reported no remaining Neurogene position as of Q3 2023 after selling out during the quarter.
Lynx1 Capital Management sold 154,728 Neurogene shares in Q3 2023, an estimated $2.57M.
Lynx1 Capital Management first reported a position in Neurogene in Q4 2022 and held it in 3 quarters.
Lynx1 Capital Management's Neurogene position peaked at $2.57M in Q2 2023.
31 funds tracked by Wall St. Rank held Neurogene as of Q3 2023.

Based on Lynx1 Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.